Very positive in all regards, especially "Proof of Concept" of their SB 728T HIV clinical trials. Ed stated that additional updates from the trials will be presented in 1st half 2013 . . . . possibly at the upcoming CROI conference in March (as late breaking results). Phase I results released in September of 2012 showed an unprecedented and durable growth in CD4+ T cells and Ed seemed to build upon that at the JPM conference. They did not just stop there in their presentation, they also indicated that they have a workable delivery system that until this point, hampered the ZFN technology a bit. I'm not clinically versed to explain how this is accomplished, but it represents a big advancement for all future ZFN gene edited infusions. Also, mentioned that all commercial partnerships (DOW, SIAL, KBLB and Shire) are all progressing or expanding nicely. 2012 had record royalties for SGMO.
Second straight day of double digit % gains on significant volume. With any follow through and cooperation from the markets, we might be able to establish a higher base and finally leave the $6's behind us for good. We should be trading in the mid teens IMO with just the sheer potential this company has.
The replay of the JPM conference is here:
investor.sangamo.com
A recent news report of expanded clinical trials (also discussed in the JPM conference) is below:
RICHMOND, Calif., Jan. 9, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the initiation of two new Phase 2 clinical studies (SB-728-1101 and SB-728-902, Cohort 5) in its program to develop a "functional cure" for HIV/AIDS. Sangamo's ZFP Therapeutic® approach (SB-728-T) generates T-cells that are resistant to HIV infection using its zinc finger nuclease (ZFN) technology to permanently disrupt the DNA sequence encoding CCR5, a co-receptor used by HIV to enter cells. The company expects to present data from its SB-728-T HIV clinical trials at appropriate medical meetings in 2012.
Full transcript here:
http://investor.sangamo.com/common/mobile/iphone/releasedetail.cfm?ReleaseID=705990&CompanyID=SGMO&mobileid= |
